There is little evidence to support the safety and efficacy of bioresorbable scaffolds (BRS) for the treatment of chronic total occlusions (CTO). This multicenter registry included consecutive patients with CTO receiving BRS (Absorb; Abbott Vascular) vs. 2nd generation drug eluting stents (DES). Primary end point was target vessel failure at long term (composite...
This small study presented at ESC and simultaneously published in the European Heart Journal evaluated patients undergoing acute coronary syndrome caused by plaque erosion identified by optical computed tomography (OCT). The study showed it can be managed with conservative antithrombotic therapy and without stenting. Patients with plaque erosion can receive dual antiplatelet therapy, ticagrelor and aspirin...
The largest randomized trial in history found no difference in the primary endpoint of death and nonfatal infarction between current conventional stents and drug-eluting stents at over 5 years in patients with stable or unstable coronary disease. As expected, NORSTENT did find a difference in revascularization rates between both groups. This study presented at the...
Original Title: Long-Term Outcome after Carotid Artery Stenting. A Population-Based Matched Cohort Study. Reference: Stroke. 2016 Jul 12. [Epub ahead of print]. In the prevention of stroke, carotid artery stenting (CAS) is far less invasive than endarterectomy, but its long term outcomes remain unclear. This large cohort study compared the long term outcomes of...
Original Title: Incidence and Clinical Outcome of Stent Fractures on the Basis of 6555 Patients and 16482 Drug Eluting Stents From 4 Centers. Reference: Kan J et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1115-23. Courtesy of Dr. Guillermo Migliaro. Stent fracture (SF) has been associated with instent restenosis (ISR), stent thrombosis (ST) and repeat revascularization...
Original Title: Long-Term Results of Everolimus-Eluting Stents versus Drug-Eluting Balloons in Patients with Bare-Metal In-Stent Restenosis 3-Year Follow-Up of the RIBS V Clinical Trial. Reference: Alfonso F. et al. JACC Cardiovasc Interv. 2016 Jun 27;9(12):1246-55. Courtesy of Dr. Agustín Vecchia. RIBS V 3 year follow up Stents have become the gold standard for...
Original Title: Stent Thrombosis with Drug Eluting Stents and Bioresorbable Scaffolds. Evidence from a Network Meta-Analysis of 147 trials. Reference: Kang S et al. J Am Coll Cardiol Intv 2016 doi 10.1016. Courtesy of Dr. Guillermo Migliaro. When treating heart disease, drug eluting stents (DES) have become essential for PCI. Its main advantage lies on...
Original Title: Biolimus A9 drug-coated stent vs. bare metal stent in patients presenting with ACS. A pre-specified LEADERS FREE ACS sub-study. Presenter: C.K. Naber. In ACS patients with high bleeding risk, guidelines recommend 3 to 6 months of dual ATP treatment for DES implantation or one month in case of conventional stenting. The...
Original Title: Revascularization in Patients with Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus Eluting Stents vs Coronary Artery Bypass Graft Surgery Reference: Bangalore et al. Circulation. 2016 May 5. Epub ahead of print. Courtesy of Dr. Guillermo Migliaro. Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary...
Francisco Chamié, Daniel Chamié, Luiz Carlos do Nascimento Simões, Renata Mattos Silva